Abstract
Dyslipidemia represents a major risk factor for cardiovascular disease. In addition, severe hypertriglyceridemia is an important cause of acute pancreatitis. Accordingly, the increase in serum lipid levels that is observed during pregnancy has potentially important implications. The management of dyslipidemia in pregnancy is further complicated by the lack of safety data during this period for most of the lipid-lowering agents. In the present review, we discuss the most important lipid disorders in pregnant women and their management. Pregnancy is characterized by increases in both low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, which might result in severe complications both for the mother and the fetus. Accordingly, LDL-C and triglyceride levels should be monitored during pregnancy, particularly in women with a history of dyslipidemia. Diet is the mainstay of management of dyslipidemia in pregnant women and apheresis can also be considered in patients with homozygous familial hypercholesterolemia or severe hypertriglyceridemia. However, there is a pressing need for studies that evaluate the safety of lipid-lowering agents during pregnancy.
Keywords: Dyslipidemia, pregnancy, statins, fibrates, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia.
Current Pharmaceutical Design
Title:Lipid Disorders in Pregnancy
Volume: 27 Issue: 36
Author(s): Anastasios Liberis*, Stamatis Petousis and Panagiotis Tsikouras
Affiliation:
- Second Department of Obstetrics and Gynecology, Medical School, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki 54250,Greece
Keywords: Dyslipidemia, pregnancy, statins, fibrates, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia.
Abstract: Dyslipidemia represents a major risk factor for cardiovascular disease. In addition, severe hypertriglyceridemia is an important cause of acute pancreatitis. Accordingly, the increase in serum lipid levels that is observed during pregnancy has potentially important implications. The management of dyslipidemia in pregnancy is further complicated by the lack of safety data during this period for most of the lipid-lowering agents. In the present review, we discuss the most important lipid disorders in pregnant women and their management. Pregnancy is characterized by increases in both low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, which might result in severe complications both for the mother and the fetus. Accordingly, LDL-C and triglyceride levels should be monitored during pregnancy, particularly in women with a history of dyslipidemia. Diet is the mainstay of management of dyslipidemia in pregnant women and apheresis can also be considered in patients with homozygous familial hypercholesterolemia or severe hypertriglyceridemia. However, there is a pressing need for studies that evaluate the safety of lipid-lowering agents during pregnancy.
Export Options
About this article
Cite this article as:
Liberis Anastasios *, Petousis Stamatis and Tsikouras Panagiotis , Lipid Disorders in Pregnancy, Current Pharmaceutical Design 2021; 27 (36) . https://dx.doi.org/10.2174/1381612827666210421103245
DOI https://dx.doi.org/10.2174/1381612827666210421103245 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Treatment Considerations of Clinical Physician on Hypertension Management in Asia
Current Hypertension Reviews Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Antiviral and Virucidal Activities of Natural Products
Current Medicinal Chemistry Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Synthesis, Characterization and Biological Activities of New Symmetric Bis-1,2,3-Triazoles with Click Chemistry
Medicinal Chemistry Enzyme Inhibitory Effect and Antioxidant Properties of Astragalus lagurus Extracts
Current Enzyme Inhibition Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)
Current Pharmaceutical Design The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design Cell Death in Mammalian Development
Current Pharmaceutical Design Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction
Current Vascular Pharmacology Ivabradine: A Current Overview
Current Clinical Pharmacology Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Transmucosal Delivery of Metformin- A Comprehensive Study
Current Drug Delivery